Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lung cancer epidemiology
- Lung cancer stage distribution
- Lung cancer is a heterogeneous disease
- Molecular distribution of NSCLC
- Molecular distribution by smoking
- Improved survival associated with targeted therapy
- Epidermal growth factor receptor (EGFR) biology
- Oncogenic EGFR mutations
- Patient characteristics
- EGFR targeted therapy
- Current US FDA approved EGFR TKIs
- Clinical trials of EGFR TKIs vs. chemo
- EGFR TKI clinical trials
- EGFR exon 20 insertion (1)
- EGFR exon 20 insertion (2)
- Selected EGFR exon 20 inhibitors in development
- Mechanism of resistance after 1st/2nd generation EGFR inhibitors
- Common mechanisms of resistance
- Mechanism of resistance: T790M
- T790M testing: tissue vs. blood
- Osimertinib as a treatment for T790M
- Osimertinib: AURA-3 trial overview
- Osimertinib: AURA-3 results
- Non-osimertinib T790M inhibitors
- Osimertinib as first line therapy - FLAURA (1)
- Osimertinib as first line therapy - FLAURA (2)
- Issues with using osimertinib as a first line therapy
- Mechanism of resistance after 3rd generation TKIs
- Post-osimertinib mechanisms of resistance
- Mechanism of resistance: C797S
- Mechanism of resistance: MET (1)
- Mechanism of resistance: MET (2)
- EGFR/MET dual inhibition - Tatton trial
- EGFR/MET dual inhibition
- EGFR/MET dual inhibition in EGFR+ patients
- EGFR/MET: challenges
- EGFR mutant NSCLC: future treatment approaches
- Ongoing clinical trials in an EGFR resistance setting
- EGFR mutant NSCLC: ongoing questions
- Conclusions
Topics Covered
- Lung cancer occurrence and distribution
- Effectiveness of targeted therapies
- Exon 20 mutations
- Common mechanisms of resistance
- Osimertinib as a treatment for T790M
- MET and C797S mutations
- Current treatment approaches
- Ongoing questions faced by the NSCLC community
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Baik, C. (2019, September 26). Update on EGFR-mutated non-small cell lung cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/MVXA5374.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Christina Baik has given the following financial disclosures: Pfizer; Novartis; Celgene; Loxo Oncology; Genentech; Daiichi Sankyo; Blueprint Medicines; Spectrum; NIH/NCI – grant/research funding to institution. AstraZeneca; F. Hoffman-La Roche AG – grant/research funding to institution and consulting fees
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my name is Christina Baik.
I'm a Thoracic Oncologist,
at the University of Washington,
and Fred Hutchinson Cancer Research Center, in Seattle, Washington.
Today I'll be giving you an update on EGFR mutated non-small-cell lung cancer,
which is an area that has advanced significantly in the past several years.
0:21
Before I go into this topic,
I'd like to start with some basic epidemiologic information on lung cancer.
Globally, lung cancer has the highest mortality rate in men,
and second highest in women.
In the United States,
lung cancer has the highest mortality and
second highest incidence rate with approximately 228,000 new cases,
and 143,000 deaths in 2019.
In the western population,
80 percent of lung cancer is attributed to smoking,
which means that about 20 percent of lung cancer patients do not have a smoking history.
This number is even higher in other parts of the world,
especially in East Asia.
Fortunately, lung cancer incidence and mortality,
at least in the United States,
have been trending down,
likely reflecting the decrease in smoking prevalence.
There also have been other interesting changes such as,
recent data showing that among the younger non-Hispanic whites and Hispanics,
lung cancer incidence has become higher in women,
and the reason for this is not entirely clear and really deserves further investigation.
1:27
Unfortunately, most patients are diagnosed with lung cancer at late stages
which is still associated with a poor prognosis despite advances in therapy.
This is data from the USCO database from 2009- 2015,
which shows that almost 60 percent of patients are
diagnosed when their disease has already metastasized,
and the five year survival rate for these patients is still around five percent.